Stock screener

CLYM

Conviction 80HealthcareScan · Tue, Sep 8, 2026
CLYM$15.89+2.38%
ResistanceSupportVol 14Insider sell
63 bars
Vol MA14 1.66M
Jun 9Jun 26Jul 16Aug 3Aug 20Sep 8
Climb Bio, Inc.PHARMACEUTICAL PREPARATIONSwww.climbbio.com ↗
Price15.89
Change+2.38%
Gap+0.39%
Rel volume0.78×
Avg volume1.62M
Avg $ vol25.23M
SMA 2015.77
SMA 5014.09
SMA 2008.78
Price vs 50+12.75%
Price vs 200+81.00%
MA stackbullish
50/200 cross—
Supertrenddown · 17.79
RSI (14)56
MACD hist-0.19
MACD crossbear · 7d
Stoch %K / %D53 / 43
ADX (14)27
+DI / −DI20 / 22
RSI divergenceBearish
MACD divergenceBearish
ATR %+7.93%
ADR %8.29%
52w high17.84
52w low1.64
From 52w high-10.93%
Above 52w low+868.90%
New 52w highNo
SqueezeOff
Bollinger width32.33%
%B0.52
Donchian pos53.44%
Donchian high18.33
Donchian low13.09
AVWAP (52w high)15.08
vs AVWAP high+5.39%
AVWAP (52w low)8.48
vs AVWAP low+87.37%
OBV trendFlat
Chaikin MF (20)0.16
Today vs 20d0.78×
Avg vol (14d)1.66M
Avg vol (20d)1.62M
Avg $ vol (20d)25.23M
Market cap912.66M
RS 3m (vs SPY)+42.68%
RS 6m (vs SPY)+101.61%
RS line new highNo
Trend template8/8
Technical rank93.7
1 week+15.73%
1 month+13.50%
3 months+47.54%
6 months+119.17%
1 year+564.85%
YTD+323.73%
P/E-15.25
P/B3.81
P/S—
P/FCF-16.73
EPS-0.8800
Div yield—
ROE-24.99%
ROA-24.30%
Debt/Eq—
Current31.45
EV/EBITDA-12.81
Gross margin—
Net margin—
Rev growth—
EPS growth19.01%
Price target28.11
Target upside76.90%
Analyst ratingBuy
Institutional101.37%
Ent. value868.56M
Revenue—
Net income-13.5M
Gross profit—
Free cash flow-54.54M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out57.26M
Employees29
ListedTue, Aug 10, 2021
Free float19.95M
Float %41.8%
Short interest7.56M
Days to cover6.3d
Short volume63.4%
Squeeze score81 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.18 vs −$0.22
Last surprise+18.2% beat
Setup gradeA
Conviction80 / 100
Pattern quality—
Tech rank93.7 / 100
Group rank96 / 100 · Leading
Status laneNo active setup
Setup direction—
Pattern family
Resistance18.23
Support11.56
Days since event—
Candle confirm—
News sentiment—

Financials as of Tue, Jun 30, 2026 · quarterly.

Recent news

Congress activity

Disclosed STOCK Act trades in CLYM

All disclosures →
No recent disclosed trades by Congress in CLYM. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in CLYM · 8 buys · 2 sells

InsiderSideShares
Brennan Aoife
President and CEO · Common Stock · 2026-06-29
Sell30.9K
Brennan Aoife
President and CEO · Restricted Stock Units · 2026-06-27
Exercise68.75K
Brennan Aoife
President and CEO · Common Stock · 2026-06-27
Exercise68.75K
RA Capital Nexus Fund III, L.P.
Director · Stock Option (Right to Buy) · 2026-06-05
Grant40K
Drapkin Kimberlee C
Director · Stock Option (Right to Buy) · 2026-06-05
Grant40K
WILLIAMS DOUGLAS E
Director · Stock Option (Right to Buy) · 2026-06-05
Grant40K
Thomas Stephen Basil
Director · Stock Option (Right to Buy) · 2026-06-05
Grant40K
RA CAPITAL MANAGEMENT, L.P.
Director · Stock Option (Right to Buy) · 2026-06-05
Grant40K
RA Capital Nexus Fund II, L.P.
Director · Stock Option (Right to Buy) · 2026-06-05
Grant40K
RA Capital Nexus Fund, L.P.
Director · Stock Option (Right to Buy) · 2026-06-05
Grant40K

SEC filings

EDGAR filings in CLYM · 10 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.